Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
TScan Therapeutics (TCRX) Stock Price & Analysis
147 Followers
TCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.93 - $9.09
Previous Close$8.01
Volume225.42K
Average Volume (3M)212.37K
Market Cap
$369.27M
Enterprise Value$269.66M
Total Cash (Recent Filing)$192.04M
Total Debt (Recent Filing)$92.43M
Price to Earnings (P/E)-4.2
Beta0.26
Next Earnings
Aug 08, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding52,862,805
10 Day Avg. Volume162,509
30 Day Avg. Volume212,371
Standard Deviation0.28
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.54
Price to Sales (P/S)20.75
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.81
Enterprise Value/Gross Profit12.81
Enterprise Value/Ebitda-6.96
Forecast
1Y Price Target
$12.00Price Target Upside33.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
TScan Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressInitial solid tumor data expected with progress in TScan's research and development.
Clinical Trial MilestonesThe company has dosed the first patient in a Phase 1 trial for its solid tumor TCR-T clinical program.
Financial StabilityTScan has a solid cash runway into 4Q26, providing financial stability for ongoing research and trials.
Bears Say
Clinical Trial ResultsPatients on the control arm have mixed outcomes, with some showing mixed chimerism or MRD positivity, and there were several relapses.
Financial HealthReturn on Equity TTM is -65.28%, highlighting current operational losses which could be a concern for potential investors.
Financial SustainabilityA high annualized cash burn rate indicates significant ongoing expenses relative to the company's financial resources.
---
Ownership Overview
22.74% Insiders
6.09% Mutual Funds
19.13% Other Institutional Investors
52.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $1.93 and its highest was $9.09 in the past 12 months.
What is TScan Therapeutics’s market cap?
Currently, no data Available
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 85 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on May 13, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.259 by -$0.061.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -$0.29.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 46,100,730 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.259. Following the earnings report the stock price went up 3.622%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Among the largest hedge funds holding TScan Therapeutics’s share is Baker Bros Advisors LP. It holds TScan Therapeutics’s shares valued at 16M.
---
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (33.48% Upside)
$12.00 (33.48% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.81%
12-Months-Change
Fundamentals
Return on Equity
-71.29%
Trailing 12-Months
Asset Growth
36.70%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
---
TCRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(33.48% Upside)
Technical Analysis
Applied Therapeutics
―
Adverum Biotechnologies
―
Arvinas Holding Company
―
Kala Pharmaceuticals
―
Best Analysts Covering TCRX
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+80.18%
reiterated a buy rating yesterday
Copying Andrew Fein's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +80.18% per trade.
---